A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
暂无分享,去创建一个
R. Larson | J. Sinkule | D. Han | K. E. Choi | K. Daly
[1] L. Booker,et al. Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy. , 1985, European journal of cancer & clinical oncology.
[2] P. Schein,et al. Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites. , 1984, Seminars in oncology.
[3] Cross Rj. Clinical safety and tolerance of mitoxantrone. , 1984 .
[4] J. Moore,et al. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. , 1984, Seminars in oncology.
[5] W. Evans,et al. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. , 1984, Cancer research.
[6] R. Wallace,et al. Molecular and biochemical pharmacology of mitoxantrone. , 1983, Cancer treatment reviews.
[7] D. Alberts,et al. Disposition of mitoxantrone in patients. , 1983, Cancer treatment reviews.
[8] B. Barlogie,et al. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro. , 1983, Cancer research.
[9] R. Angier,et al. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. , 1979, Cancer research.
[10] H. Preisler. Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.
[11] S. Riegelman,et al. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. , 1970, Journal of pharmaceutical sciences.